

line 1-2, change "characterized in that" to --wherein--.

Claim 3, line 1, change "Avian" to --The avian--;

line 1-2, change "characterized in that" to --wherein--;

line 2, change "derived" to --obtained--.

Claim 5, line 1, change "derived" to --obtained--.

Please amend claims 4 and 6-13 as follows:

6A 6A. (Amended) ~~Immortal, untransformed avian cell line, which is~~

selected from the group consisting of:

[- cell line TDF-2A bcl-2, which is deposited in the CNCM (Collection Nationale de Cultures de Microorganismes de l'Institut Pasteur [Pasteur Institute National Collection of Microorganism Cultures]) under reference number I-1709.

- cell line TCF04.10, which is deposited in the CNCM under reference number I-1710

- cell line TCF-4.10 bcl-2, which is deposited in the CNCM under reference number I-1711.]

- cell line TDF-2A bcl-2, which is deposited in the CNCM (Pasteur Institute National Collection of Microorganism Cultures) under reference number I-1709;
cell line TCF-4.10, which is deposited in the CNCM under the reference number I-1710; and cell line TCF-4.10 bcl2, which is deposited in the CNCM under reference number I-1711.

6 6. (Amended) [Cells] The cells according to claim 5, [characterized in that] wherein they [contain at least one] comprise an expression cassette which

[comprises at least one] expresses a nucleotide sequence [encoding a molecule of industrial relevance].

9. (Amended) [Cells] The cells according to Claim 8, [characterized in that] wherein the nucleotide sequence encodes a viral [subunit of the] peptide, protein or glycoprotein type or encodes protein molecules [such as hormones].

10. (Amended) [Cells] The cells according to Claim 7, [characterized in that] wherein they are infected[, preferably chronically,] with a virus which is able to multiply in these cells.

11. (Twice Amended) [Cells] The cells according to Claim 5,
[characterized in that] wherein they contain [a survival or] an anti-apoptotic gene [other than bcl-2, which gene is preferably] selected from the group consisting of p19E1B from human adenovirus, LMP-1 from Epstein Barr virus, BHRF1 from Epstein Barr virus, ICP34.5 from herpes simplex virus and p35 from baculovirus.

12. (Twice Amended) [Cells] The cells according to Claim 5,
[characterized in that] wherein ^{the cells comprise} _{they integrate} ^{comprises} [vectors which are able to overexpress one or more of the genes involved in controlling the cell cycle in order to increase the rate of proliferation] a vector comprising a gene encoding viral receptor.

11. (Twice Amended) [Cells] The cells according to Claim 5,
[characterized in that] wherein they integrate [genes which encode] a vector comprising a gene encoding a viral receptors receptor.

14. (Twice Amended) [Cells] The cells according to Claim 5,
[characterized in that] wherein ^{the cells comprise} _{they integrate} ^{comprises} [oncogenes which are able to accelerate cell growth] a vector comprising a gene encoding an oncogene.

Sub C
B3 Ct

13. (Twice Amended) [Method] A method for producing [molecules of industrial relevance or viruses, comprising culturing cells according to Claim 5] viruses or viral peptide, protein, glycoprotein, or protein molecules which comprises culturing the cells selected from claims 5 to 12.

Please add the following claims 14-18:

--14. The avian cell line according to claim 1, wherein the anti-apoptotic gene is the bcl-2 gene.

~~4~~ 15. The avian cell line according to claim 1, wherein the cells comprise, integrated into their genome, the SV40 T+t gene.

~~5~~ 16. The avian cell line according to claim ~~15~~, wherein the SV40 T+t gene is under the control of the MTI promoter.

17. The avian cell line according to claim 1, wherein the cells integrate into their genome the vector pDAMT.

18. The avian cell line according to claim 1, wherein the cells integrate into their genome the vector ppMT.--

REMARKS

Reconsideration of this application is respectfully requested.

Specification:

An abstract has been provided as requested.